Abstract

The invention relates to a microchannel device for preparation of sperm, the device comprising: an inlet; an extraction zone; and a channel fluidly connecting the inlet to the extraction zone; wherein the channel comprises a plurality of orienting features operable to bias a direction of sperm cell movement within the channel towards a preferred direction; and wherein the channel has a length of approximately 1 centimetre or greater. Further, the invention relates to a method of sperm preparation using the microchannel device.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A formulation comprises polysaccharide aggregates suspended in an aqueous medium and a salt. The only polysaccharides present in the formulation are the polysaccharides which form the aggregates. The formulation may find use in the treatment or prevention of fibrosis or scarring. The formulation can be prepared by dissolving a polysaccharide in an aqueous medium at a temperature of at least 50 °C to form a solution, cooling the solution, and adding a salt to the cooled solution while stirring.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 47/02 - Inorganic compounds
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The present disclosure relates to the use of ATM inhibitors, such as AZ1390 and related compounds, in the treatment of various neurological conditions, by protecting against or treating neuronal damage or neuronal degeneration, including traumatic injury, such as spinal cord injury (SCI).

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A method of providing a prognosis to a subject, the method comprising: i. providing a biological sample obtained from the subject; ii. determining the level of a panel of biomarkers comprising or consisting of SPATA 19, SPACA3, TSPY3, TCEA2, TSGA10, and LUZP4 in the sample; iii. comparing the level of the panel of biomarkers in the sample with a reference level of the same panel of biomarkers; iv. using the results from (iii) to provide a prognosis to the subject. More particularly, a method of providing a prognosis to a subject with cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The invention relates to a novel phosphoantigen (PAg) prodrug compound which provides for a potent activation of therapeutically active γδ T cells. The PAg prodrug compound of the in- vention can be used for the preparation of therapeutically active γδ T cells as well as in the immunotherapy of different diseases, and in particular different types of cancer. The invention further relates to a method for expanding γδ T-cells ex vivo which makes use of the PAg pro-drug compound of the invention. Also provided are γδ T-cells which have been expanded with the PAg prodrug compound of the invention and pharmaceutical compositions comprising such expanded cells and/or the PAg prodrug compound of the invention.

IPC Classes  ?

• A61P 19/00 - Drugs for skeletal disorders
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07F 9/44 - Amides thereof

Abstract

This detection system comprises: a detection signal acquisition unit 306 that acquires, as a detection signal, a signal from an object being detected; and a noise-removed signal acquisition unit 307 that inputs the detection signal to a noise removal model 304 trained using noise signals obtained when no object is detected, and acquires at least one noise-removed signal, from which noise has been removed.

IPC Classes  ?

• G01N 15/1429 - Signal processing

Abstract

The invention provides an assay useful in predicting risk of capecitabine-induced toxicity in a subject. The subject may be screened for the presence of at least one polymorphism of the invention. Suitable polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing capecitabine-induced toxicity; a negative result may indicate a decreased risk of developing capecitabine-induced toxicity.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of forming an implant for the repair of defects in bone. the method comprises the steps of: electrospinning bioactive glass fibres: compressing the electrospun bioactive glass fibres to form a compressed body: heating the compressed body to bond the fibres to form a shaped body: heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.

IPC Classes  ?

• A61L 27/10 - Ceramics or glasses
• A61L 27/38 - Animal cells

Abstract

A method of isolating or suppressing forced oscillations in a power grid by utilising a wind turbine system comprising a wind turbine for capturing wind power, a generator driven by the wind turbine, and a power converter configured to control the rotational speed of the generator for controlling a supply of active power to the power grid. The power converter is further configured to supply reactive power to the power grid independently from the supply of active power. The method comprising the steps of: obtaining measurements of a forced oscillation occurring within the power grid; controlling the converter to supply active and reactive corrective oscillating power to the power grid in response to the measured forced oscillation such that the corrective oscillating power suppresses the forced oscillations.

IPC Classes  ?

• H02J 3/24 - Arrangements for preventing or reducing oscillations of power in networks
• F03D 7/02 - Controlling wind motors the wind motors having rotation axis substantially parallel to the air flow entering the rotor
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers

Abstract

A mobile platform (C) comprising an energy storage system, the system comprising a sorbent and sorbate pair, the system further comprising a first chamber (11), a second chamber (13), a fluid flow conduit (12) fluidly connecting the first chamber (11) and the second chamber (13), and a microwave generator (21), wherein the microwave generator (21) is operable in use to desorb the sorbate from the sorbent in the first chamber (11) to release thermal energy from the second chamber (13), and wherein the second chamber (13) is thermally connectable to a source of fluid to condense the sorbate and thereby heat the fluid.

IPC Classes  ?

• B60H 1/32 - Cooling devices
• F28D 20/00 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or

Abstract

An apparatus for driving atoms of an atom cloud into a targeted quantum state is provided, the apparatus comprising: an atom source for releasing a cloud of atoms to be driven into a targeted quantum state; a laser system configured to generate a laser beam to be directed onto the atom cloud in use, the laser beam having a frequency corresponding to a resonant frequency of an atomic transition for exciting the atoms into the targeted quantum state; a modulator configured to, in use, modulate the frequency of the laser beam responsive to an input signal; a waveform generator coupled to the modulator and configured to, in use, generate an input signal for the modulator, wherein the input signal is arranged to cause the modulator to modulate the laser light to generate a comb of frequencies around the resonant frequency of the atomic transition, the frequency comb including a plurality of peaks, each peak being separated by a frequency spacing, δω, that is determined based on a Rabi frequency, Ω, of the atomic transition to drive atoms of the atom cloud into a targeted quantum state.

IPC Classes  ?

• G01V 7/04 - Electric, photoelectric, or magnetic indicating or recording means
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

A method of diagnosis utilising a lab-on-a-chip (LoC). The LoC comprising an inlet well (61) and a succession of sampling wells (11,21,31,41,51) arranged in fluid communication via capillary channels (14,24,34,44,54) and a filter (15,25,34,45,55) provided between each of the inlet well (61) and a first sampling well (51) and between adjacent sampling wells (11,21,31,41) with each successive filter having a smaller pore size. The method comprising: applying a biofluid sample comprising extracellular vesicles to the inlet well (61); the biofluid sample being drawn along the succession of sampling wells (11,21,31,41,51); the extracellular vesicles being separated by the filters (15,25,35,45) into a plurality of subclasses determined by their size, each subclass being isolated in a separate sampling well (11,21,31,41,51) and collecting identifying data on the extracellular vesicles in each sampling well (11,21,31,41,51).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 21/65 - Raman scattering

Abstract

A lab-on-a-chip (LoC) (1) comprising a plurality of sampling wells (51, 41) and a nano-porous filter (45). A first sampling well (51) in fluid communication with a second sampling well (41) via a flow path. The nano-porous filter (45) being provided in the first sampling well (51).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present disclosure relates to methods and products for use in detecting target RNA sequences in a sample, based on a process which nicks the DNA strand of a DNA/RNA duplex and amplifies a product thereof

IPC Classes  ?

• C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention concerns a peptide comprising the amino acid sequence SVTEQGAELSNEER, or variants thereof for use in the prophylaxis or treatment of obesity-associated inflammatory conditions such as obesity-induced chronic low-grade systemic inflammation and pancreatic beta-cell damage. Methods of treatment or prophylaxis of obesity-associated inflammatory conditions comprise administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER, or variants thereof, to a patient in need thereof.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.

IPC Classes  ?

• G01V 7/02 - Measuring gravitational fields or wavesGravimetric prospecting or detecting Details
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.

IPC Classes  ?

• H01S 3/107 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity using electro-optic devices, e.g. exhibiting Pockels or Kerr effect
• G01V 7/04 - Electric, photoelectric, or magnetic indicating or recording means
• H01S 3/067 - Fibre lasers
• H01S 3/106 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity
• H01S 3/109 - Frequency multiplication, e.g. harmonic generation
• H01S 3/16 - Solid materials

Abstract

The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The invention relates to a peptide conjugate comprising a peptide covalently linked to a label, wherein the peptide comprises an amino acid sequence of a protein ligand that binds at least one class B1 G protein-coupled receptor, wherein the peptide is covalently linked to the label. The protein ligand is preferably an agonist, antagonist and/or co-agonist of at least one class B1 G protein-coupled receptor, preferably from the Glucagon-like subfamily. The agonist, antagonist and/or co-agonist is preferably selected from tirzepatide, LY3437943 or GIF. The invention further relates to kits comprising the peptide conjugate according to the invention or means for assembling the conjugate, as well as methods for using the peptide conjugate according to the invention.

IPC Classes  ?

• C07K 14/605 - Glucagons
• A61K 38/26 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates generally to materials and methods of inhibiting Long Terminal Repeat Transposable Elements (LTR-TEs) during propagation of a plant by use of a reverse transcriptase inhibitor. Methods include propagation by plant tissue culture, comprising culturing an initial plant tissue in a culture medium comprising a reverse transcriptase inhibitor to obtain the cultured plant tissue, whereby inhibiting LTR-TEs leads to reduction in somaclonal variation in cultured plant tissue. Also provided are related media adapted for such culture, and plants and tissues which have reduced genetic variation as a result of the method.

IPC Classes  ?

• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

Provided is a method of activating T cells, the method including contacting the T cells with a plurality of magnetic nanoparticles (MNPs), wherein each MNP is functionalized with a T cell receptor (TCR) binding moiety, and exposing the T cells to a magnetic field. The method finds utility in the treatment of cancer and autoimmune disease.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 37/04 - Immunostimulants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A phase shifter (400) comprises a substrate integrated waveguide, at least one controllable element (420), at least one fluid channel, and a liquid disposed in the at least one fluid channel. The substrate integrated waveguide comprises a substrate, a first conductor layer on a first side of the substrate, a second conductor layer on a second side of the substrate, and a plurality of edge vias (403) defining a conducting path between the first conductor layer and the second conductor layer. The first conductor layer, second conductor layer and the plurality of edge vias (403) define a waveguide core for propagation of radio frequency signals. Each controllable element (420) comprises a pad, a via and a slot, wherein the pad and slot are defined in one of the first conductor layer or the second conductor layer, the slot isolating the pad, and the via defines a conducting path between the pad and the other of the first conductor layer and the second conductor layer. The at least one fluid channel is disposed on the first conductor layer and/or the second conductor layer and is configured to allow fluid communication with each slot. The at least one controllable element (420) is configured to be controlled by movement of the liquid within the at least one fluid channel, thereby causing a phase shift in the radio frequency signals as a result of bridging of at least one slot by the liquid.

IPC Classes  ?

• H01P 1/18 - Phase-shifters

Abstract

The invention relates to an assay. More specifically, the invention relates to an assay for predicting cardiovascular toxicity of a chemotherapeutic agent.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention provides a method of stratifying test subjects with Polycystic Ovary Syndrome (PCOS) into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising: (a) providing a test sample from a test subject with PCOS; (b) determining the concentration/level in the test sample of at least one ovarian androgen steroid and/or a derivative thereof, and at least one adrenal steroid and/or derivative thereof; and (c) using the results from (b) to predict if the subject will respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, therapeutic treatment with an AKR1C3 inhibitor, or therapeutic treatment with a 5alpha-reductase inhibitor.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

The present disclosure provides lipid compounds useful in treating inflammatory skin diseases.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate

Abstract

An implantable device (101) for drug delivery to a patient, the device comprising a housing (103) defining an enclosed space (106), a catheter port (102) that provides fluid access to the enclosed space, a permeable release zone (105) that permits drug release from the enclosed space, and an attachment portion (104) for attaching the housing at a location, such that, in use, the implantable device can be placed within the body of the patient and attached, using the attachment portion, at a location such that the release zone is adjacent to a treatment site, and whereby a drug composition in fluid form can be provided to the enclosed space via a catheter (108) and the catheter port, and the drug can be released to the treatment site via the permeable release zone.

IPC Classes  ?

• A61M 39/02 - Access sites
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

A system (100) for metal production, the system comprising: a reducing furnace (110) configured to receive metal ore (101) and process gas (102) and to output hot metal (115) and reducing furnace top gas (111); and a first thermochemical reactor (130) configured to, in a first mode, receive at least a portion (163) of the reducing furnace top gas (111), and to produce carbon monoxide from carbon dioxide in the portion (163) of the blast reducing furnace top gas (111) by oxidation of a thermochemical compound and to return at least a portion of the produced carbon monoxide (151) to the reducing furnace (110).

IPC Classes  ?

• C21B 5/00 - Making pig-iron in the blast furnace
• C21B 5/06 - Making pig-iron in the blast furnace using top gas in the blast furnace process
• C21B 7/00 - Blast furnaces
• C21B 13/00 - Making spongy iron or liquid steel, by direct processes
• C21B 13/14 - Multi-stage processes
• F27B 1/22 - Arrangements of heat-exchange apparatus
• F27D 17/00 - Arrangements for using waste heatArrangements for using, or disposing of, waste gases

Abstract

The invention relates to GC-globulin, or a variant thereof, for use in treating diabetes.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A system for improving cognitive function is disclosed. The system comprises a non-invasive brain stimulation device (150); a human computer interface; and a computer (101) configured to control the non-invasive brain stimulation device (150) and the human computer interface. The computer (101) controls the brain stimulation device (150) and the human computer interface to assess a subject's baseline cognitive function by interaction with the subject using the human computer interface. If the subject's baseline cognitive function is impaired, the computer (101) uses the human computer interface to provide the subject with a strategy for improving performance in a cognitive function test and stimulates the subjects brain with the non-invasive brain stimulation device (150) while training the subjects cognitive function.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/383 - Somatosensory stimuli, e.g. electric stimulation

Abstract

A method of manufacturing a component (5) for use in a high temperature environment, the method comprises the sequential steps of: i) providing a first substrate (10) comprising a body having a surface, ii) securing a bonding material (13) to the surface of the first substrate (10), iii) removing at least some of the substrate (10) and bonding material (13) to provide a formation (14z) extending into the body (10), and iv) securing a second substrate (11) to the first substate using at least some of the bonding material.

IPC Classes  ?

• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 1/00 - Soldering, e.g. brazing, or unsoldering
• B23K 1/20 - Preliminary treatment of work or areas to be soldered, e.g. in respect of a galvanic coating
• B23K 20/02 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating by means of a press
• B23K 20/16 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating with interposition of special material to facilitate connection of the parts, e.g. material for absorbing or producing gas
• B23K 20/233 - Non-electric welding by applying impact or other pressure, with or without the application of heat, e.g. cladding or plating taking account of the properties of the materials to be welded without ferrous layer
• F01D 5/00 - BladesBlade-carrying membersHeating, heat-insulating, cooling, or antivibration means on the blades or the members
• B23K 101/00 - Articles made by soldering, welding or cutting
• B23K 103/18 - Dissimilar materials

Abstract

The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1-54, which may be encoded by SEQ ID NOS: 55-110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The invention relates to a set of oligonucleotides, and a kit comprising a set of oligonucleotides where the oligonucleotides are for use in determining the HLA genotype of a DNA sample. The invention also relates to a method of determining the HLA genotype of a DNA sample. The method may be used to identify a suitable donor and/or recipient of a transplant, for paternity testing, to identify the HLA type for determination of epitope binding capability in neo-antigen prediction, or for diagnosing an immune disorder such as ankylosing spondylitis. The method preferably uses long-range PCR and long read sequencing preferably using a Type R10 nanopore.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

A photocurable resin composition comprising a crosslinker (104), the crosslinker (104) comprising plural cyclic disulphide groups and wherein the concentration of disulphide bonds in the resin composition is at least 10 wt.%.

IPC Classes  ?

• C08G 75/06 - Polythioethers from cyclic thioethers
• C08G 75/14 - Polysulfides
• C08L 81/04 - Polysulfides

Abstract

The present invention relates to the identification of novel therapeutic targets and their use in the mitigation of inflammatory pathologies. In particular, the present invention concerns the field of anti-interleukin-17A antibodies, pharmaceutical compositions comprising said antibodies and medical uses of the same. Further aspects of the invention relate to a polynucleotide encoding the anti-interleukin-17A, vectors comprising the polynucleotide and host cells incorporating said vectors. In a further aspect the invention describes a peptide for the identification of anti- interleukin-17 compounds.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/54 - Interleukins [IL]

Abstract

The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen- specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure is based in part on studies that identify upregulation of markers in response to stimulation by an antigen (also referred to as activation induced markers) to detect antigen-specific immune cells, and uses thereof. The disclosure provides methods for identifying antigen-specific T cells produced in response to stimulation by an antigen.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

dcH(t)M(t)cM(t)H(t)H(t).

IPC Classes  ?

• G01R 33/12 - Measuring magnetic properties of articles or specimens of solids or fluids
• A61B 5/0515 - Magnetic particle imaging

Abstract

The present teaching relates to peptides that are capable of regulating the trafficking of leukocytes. This has applications in the treatment and/or prophylaxis of conditions associated with leukocyte migration, including inflammatory diseases and/or musculoskeletal (MSK) loss and/or damage.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a genetic probe, wherein the genetic probe comprises: an oligonucleotide, or an oligonucleotide analogue, with a Raman-active moiety incorporated therein, wherein the Raman-active moiety is incorporated into a base of the oligonucleotide or oligonucleotide thereof; and associated methods, uses, kits and compositions for determining a single point variant nucleotide in a target nucleic acid.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 21/65 - Raman scattering

Abstract

The present disclosure describes, in part, a polymer, for example a thermoplastic polyurethane elastomer, comprising one or more subunits comprising (i) at least one dianhydrohexitole moiety (ii) at least one urethane moiety and (ill) a thiol moiety having two or more sulphur atoms. The thermoplastic polyurethane elastomers may be biodegradable and possess excellent thermoplastic properties, including outstanding toughness, resulting from its semi-crystallinity and low glass transition temperature, that surpasses many leading plastics such as nylon 6 and high-density polyethylene (HOPE) and methods of making same.

IPC Classes  ?

• C08G 18/32 - Polyhydroxy compoundsPolyaminesHydroxy amines
• C08G 75/04 - Polythioethers from mercapto compounds or metallic derivatives thereof
• C08L 75/04 - Polyurethanes
• C08G 18/81 - Unsaturated isocyanates or isothiocyanates

Abstract

The present invention relates to a system and a device for use in the diagnosis of an oral disease. Methods, kits and compositions for use in the diagnosis of oral disease are also provided. More particularly, the invention relates to a system comprising a probe which is configured to collect a fluid sample from the oral cavity of a subject, and a detector which is configured to detect in the fluid sample the presence and/or concentration of an analyte which is indicative of the oral disease.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• B01L 3/02 - BurettesPipettes

Abstract

A method (2800) of selectively leaching one or more manganese-containing phases from a mixed-phase battery electrode material comprises treating (2802) the mixed-phase battery electrode material with a solution of an acid, the acid acting as both a leaching agent and a reducing agent, so as to form a manganese-containing leachate whilst leaving at least one phase of the battery electrode material unleached, wherein the acid has a pKa greater than or equal to −2. Either or both of the leachate and the remaining electrode material may then be regenerated (2806, 2808).

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C22B 47/00 - Obtaining manganese
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/04 - Processes of manufacture in general

Abstract

A desalination system and a method for operating the desalination system. An example desalination system includes a partitioned container, a membrane container housing a cross-flow semipermeable membrane, a feed pump for supplying saline water, a recirculation pump, a main valve, a bypass valve and a purge valve. The system operates in a first pressurisation stage where saline water is provided by the feed pump while the bypass valve is open, followed by a second pressurisation stage where an upstream compartment of the container is filled and a recharge stage where the main valve is closed and concentrated saline water is purged via the purge valve. An inlet valve may be provided, which is closed in the first pressurisation stage and open in the second pressurisation stage and recharge stage.

IPC Classes  ?

• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/08 - Apparatus therefor
• B01D 61/12 - Controlling or regulating
• C02F 1/00 - Treatment of water, waste water, or sewage
• B01D 65/02 - Membrane cleaning or sterilisation
• B01D 63/10 - Spiral-wound membrane modules

Abstract

The present disclosure relates to the treatment of eye conditions, by inhibiting Chk2 kinase. Particular ocular conditions may be associated with neuronal damage/dysfunction in the eye, or neurons in communication with the eye, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption inblood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.

IPC Classes  ?

• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a sprayable antiviral formulation comprising an antiviral agent and a carrier polymer, wherein the antiviral agent comprises a sulphated polysaccharide and the carrier polymer comprises a non-sulphated polysaccharide. In particular, the present invention relates to a sprayable antiviral formulation which can be used as a nasal spray or as a multi-surface spray.

IPC Classes  ?

• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A01N 25/06 - Aerosols
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A61K 31/727 - HeparinHeparan
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The present disclosure relates to the treatment of neurological conditions, by inhibiting Chk2 kinase. Particular neurological conditions may be associated with neuronal damage/dysfunction or neurological degeneration, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.

IPC Classes  ?

• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides rotaxanes comprising a macrocycle surrounding an ion comprising a blocking group capable of trapping the macrocycle. Also provided are methods of making such rotaxanes and a method of removing the blocking group from the rotaxane, thereby allowing the ion to escape the macrocycle. The ions have been found to have anticancer, antibacterial and/or antiviral properties. Accordingly, the rotaxanes of the invention may be useful in the treatment of cancer, bacterial and/or viral diseases.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C08B 37/16 - CyclodextrinDerivatives thereof
• C08G 83/00 - Macromolecular compounds not provided for in groups

Abstract

A method for determining geometry of a face mask comprising a main body and a seal configured to engage a nasal region, cheeks and a chin of a user. The method comprises collecting (402) facial data of the user comprising a point cloud comprising a plurality of points on a skin surface in a nasal region, eye region and chin region of the user; determining (406), based on the facial data, in at least one of the eye region and the chin region of the user, an estimated face size of the user; determining (408), based on the facial data comprising the plurality of points in the nasal region, a best-fit Gaussian curve to a profile of a nose of the user; and using the estimated face size of the user and the determined Gaussian curve to select (410) parameters for a profile geometry of the face mask.

IPC Classes  ?

• A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof

Abstract

Provided is a method of diagnosing and/or monitoring traumatic brain injury (TBI) in a subject. The method comprises determining a level of at least one miRNA in a fluid sample from the subject. The miRNA may be selected from miR-425-5p, miR-502, miR-21 and miR-335. The method may involve determining whether a subject is suffering from mild-TBI or moderate-to-severe TI. Also provided is a sensor element, a detection system, composition and a kit for diagnosing and/or monitoring TBI, and a method of determining an appropriate treatment for a subject with a suspected TBI.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

There is disclosed a reconfigurable metasurface device comprising a planar dielectric substrate and a two dimensional array of substantially planar conductive elements formed on or in the dielectric substrate. The two dimensional array of substantially planar conductive elements consists of alternating rows and columns of first and second substantially planar conductive elements, the first conductive elements each having a first shape with a first width and height, and the second conductive elements each having a second shape with a second width and height. The alternating rows and columns are offset with respect to each other such that centroids of the first shapes are disposed centrally between centroids of the second shapes of each adjacent row, and centroids of the first shapes of one column are disposed centrally between centroids of the second shapes in each adjacent column. The device further comprises a conductive ground plane disposed adjacent and substantially parallel to the two dimensional array of conductive elements so as to define an air gap between the two dimensional array of conductive elements and the conductive ground plane, and a micro-actuator configured to adjust or vary a thickness of the air gap.

IPC Classes  ?

• H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
• H01Q 15/24 - Polarising devicesPolarisation filters

Abstract

Articles comprising a porous surface and having on said porous surface a coating comprising nanocellulose, methods of applying a coating comprising nanocellulose to a porous substrate, compositions comprising nanocellulose, and the use of such compositions in methods of improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01N 59/06 - AluminiumCalciumMagnesiumCompounds thereof
• A01N 59/16 - Heavy metalsCompounds thereof
• A01N 59/20 - Copper
• A01N 33/12 - Quaternary ammonium compounds
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

Provided is a method of diagnosing and/or monitoring mild traumatic brain injury (mTBI) or concussion in a subject. The method comprises determining a level of at least one miRNA in a saliva sample from the subject. Also provided is a sensor element, a detection system, composition and a kit for diagnosing and/or monitoring TBI, and a method of determining an appropriate treatment for a subject with suspected mTBI or concussion.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

There is disclosed a leaky-wave antenna device comprising a first metasurface comprising a first dielectric substrate having a first array of conductive elements and a second metasurface comprising a second dielectric substrate having a second array of conductive elements. The antenna device further comprises a conductive ground plane, a micro-actuator, and a feed comprising a pair of switchable dipoles. The first and second metasurfaces and the conductive ground plane are in a stacked arrangement and substantially parallel to one another, with the first metasurface located between the second metasurface and the conductive ground plane. A spacing between the conductive ground plane and the first metasurface is adjustable by operation of the micro-actuator. The feed is disposed between the first and second metasurfaces at a location corresponding to a centre of the first and second arrays. The leaky-wave antenna device may be operated to steer a beam over a wide range by selective energising of the pair of dipoles and by adjusting the spacing between the conductive ground plane and the first metasurface.

IPC Classes  ?

• H01Q 3/16 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system using mechanical relative movement between primary active elements and secondary devices of antennas or antenna systems for varying relative position of primary active element and a reflecting device
• H01Q 13/28 - Non-resonant leaky-waveguide or transmission-line antennas Equivalent structures causing radiation along the transmission path of a guided wave comprising elements constituting electric discontinuities and spaced in direction of wave propagation, e.g. dielectric elements or conductive elements forming artificial dielectric
• H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices

Abstract

The application discloses an atom interferometer comprising an optical cavity and method of operation thereof. The atom interferometer includes a vacuum chamber, an optical cavity, a source for providing a cloud of atoms in the optical cavity in use, and one or more light sources. The one or more light sources are for generating, in the cavity, in use a first light beam having a first polarisation and at a first frequency for a two-photon interaction in the atoms; and a counterpropagating second light beam having a second polarisation orthogonal to the first polarisation and at a second frequency for the two-photon interaction in the atoms. The atom interferometer also includes an electro-optic element arranged in the cavity to be operable to simultaneously change; the resonant frequency of the cavity for light in the first polarisation to track changes in the frequency of the first light beam to compensate for the doppler shift of the falling atoms in use; and the resonant frequency of the cavity for light in the second polarisation to track changes in frequency of the counterpropagating second light beam to compensate for the doppler shift of the falling atoms in use.

IPC Classes  ?

• G01B 9/02002 - Interferometers characterised by controlling or generating intrinsic radiation properties using two or more frequencies
• G01B 9/02001 - Interferometers characterised by controlling or generating intrinsic radiation properties
• G02F 1/03 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on ceramics or electro-optical crystals, e.g. exhibiting Pockels or Kerr effect
• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
• G01C 19/62 - Electronic or nuclear magnetic resonance gyrometers with optical pumping
• G01V 7/00 - Measuring gravitational fields or wavesGravimetric prospecting or detecting

Abstract

ActinomycetotaActinomycetotaActinomycetota phylum.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 31/04 - Antibacterial agents
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The invention relates to a method of generating bone marrow organoids from pluripotent stem cells wherein said method comprises: a) driving induced pluripotent stem cells (iPSCs) to form mesodermal aggregates; b) inducing vascular and hematopoietic commitment of the mesodermal aggregates by further culturing the mesodermal aggregates in medium, supplemented with recombinant BMP4, FGF2, VEGFA and SCF; c) embedding the mesodermal aggregates in a hydrogel, and incubating the hydrogel in a sprouting medium comprising: a media suitable for stem cell maintenance supplemented with cytokines for differentiation, to form bone marrow organoids; and optionally d) separating the bone marrow organoids from the hydrogel for further free culture.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system

Abstract

The use of a single compound or a combination of compounds which selectively inhibit both matrix metalloproteinases MMP-9 and MMP-12 in treating spinal cord injury (SCI), the secondary effects of SCI and related injury to neurological tissue are described, in particular the suppression of SCI-induced oedema, treatment of neuropathic pain, the prevention of functional decline following SCI and methods of administration.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/721 - Dextrans
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Articles comprising a surface or porous substrate and having on said surface or porous substrate a coating comprising microfibrillated cellulose or nanocellulose, methods of applying a coating comprising microfibrillated cellulose or nanocellulose to a surface or porous substrate, compositions comprising microfibrillated cellulose or nanocellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating, and improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.

IPC Classes  ?

• A41D 13/11 - Protective face masks, e.g. for surgical use, or for use in foul atmospheres
• C09D 7/63 - Additives non-macromolecular organic
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 7/20 - Diluents or solvents
• C09D 101/08 - Cellulose derivatives
• C08L 1/08 - Cellulose derivatives

Abstract

Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/02 - Inorganic compounds
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

Provided are pharmaceutical compositions comprising a sulphated polysaccharide and a shear-thinning fluid gel. The sulphated polysaccharide may, by way of example, be selected from the group consisting of: a dextran sulphate having an average molecular weight of 10,000 Da or less; heparan sulphate; fucoidan; poligeenan; furcellaran; and a carrageenan. The shear-thinning fluid gel may comprise a microgel particle forming polymer, suitably selected from one or more of the following groups: gellans; alginates; carrageenans; agarose; chitosan; pectin; agarose; agar or gelatin. The compositions disclosed may be used for the prevention and/or treatment of glaucoma. These compositions may be used for the inhibition or reduction of fibrosis. The invention also relates to the medical uses of sulphated polysaccharides, and the medical uses of shear-thinning fluid gels.

IPC Classes  ?

• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61K 31/727 - HeparinHeparan
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/06 - Antiglaucoma agents or miotics
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

An apparatus for treating TBI or TSI comprises at least two optical fibers and a light source which is operatively connected to at least one of the optical fibres. The apparatus may comprise an adapter for securing the optical fibres to the body of the subject, enabling the direct delivery of light to the brain or spinal cord. Methods and kits for treating TBI or TSI, and methods for determining the effectiveness of treatment are also provided.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

Articles comprising a surface and having on said surface a coating comprising microfibrillated cellulose, methods of applying a coating comprising microfibrillated cellulose to a surface, compositions comprising microfibrillated cellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating.

IPC Classes  ?

• C08K 3/08 - Metals
• C09D 5/14 - Paints containing biocides, e.g. fungicides, insecticides or pesticides
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 101/02 - CelluloseModified cellulose

Abstract

A method of producing a biofilm-like microorganism-polymer complex, the method comprising the step of exposing, in an aqueous medium, cells of a microorganism to a polymer comprising groups as defined by formula (la) or formula (lb), wherein: Y comprises an imine; and R2 comprises a CI-30 group. A biofilm-like microorganism-polymer complex comprising cells of a microorganism and a polymer comprising groups as defined by formula (la) and/or formula (lb). A method for producing a chemical and/or biological product using the microorganism-polymer complex, and the chemical and/or biological products obtained therefrom. A method of dispersing the microorganism-polymer complex. Polymers of formula (la) and of formula (lb).

IPC Classes  ?

• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention relates to a microchannel device for preparation of sperm, the device comprising: an inlet; an extraction zone; and a channel fluidly connecting the inlet to the extraction zone; wherein the channel comprises a plurality of orienting features operable to bias a direction of sperm cell movement within the channel towards a preferred direction; and wherein the channel has a length of approximately 1 centimetre or greater. Further, the invention relates to a method of sperm preparation using the microchannel device.

IPC Classes  ?

• A61D 19/02 - Instruments or methods for reproduction or fertilisation for artificial insemination
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 33/483 - Physical analysis of biological material
• A61D 19/00 - Instruments or methods for reproduction or fertilisation

Abstract

A method of forming an implant for the repair of defects in bone, the method comprises the steps of:. electrospinning bioactive glass fibres;. compressing the electrospun bioactive glass fibres to form a compressed body;. heating the compressed body to bond the fibres to form a shaped body;. heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.

IPC Classes  ?

• A61L 27/10 - Ceramics or glasses
• A61L 27/38 - Animal cells
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

A method of forming an implant for the repair of defects in bone, the method comprises the steps of:. electrospinning bioactive glass fibres;. compressing the electrospun bioactive glass fibres to form a compressed body;. heating the compressed body to bond the fibres to form a shaped body;. heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.

IPC Classes  ?

• A61L 27/10 - Ceramics or glasses
• A61L 27/38 - Animal cells
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present disclosure relates to the use of ATM inhibitors, such as AZ1390 and related compounds, in the treatment of various neurological conditions, by protecting against or treating neuronal damage or neuronal degeneration, including traumatic injury, such as spinal cord injury (SCI).

IPC Classes  ?

• A61K 31/4738 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents

Abstract

Provided herein are analogues of S-adenosyl-L-methionine, methods of their preparation, and complexes and kits comprising the analogues. Said analogues find use in modifying, labelling and analysing a target molecule such as a nucleic acid.

IPC Classes  ?

• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• A61K 38/45 - Transferases (2)
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12P 21/00 - Preparation of peptides or proteins
• C12N 9/10 - Transferases (2.)

Abstract

A method of providing a prognosis to a subject, the method comprising: i. providing a biological sample obtained from the subject; ii. determining the level of a panel of biomarkers comprising or consisting of SPATA 19, SPACA3, TSPY3, TCEA2, TSGA10, and LUZP4 in the sample; iii. comparing the level of the panel of biomarkers in the sample with a reference level of the same panel of biomarkers; iv. using the results from (iii) to provide a prognosis to the subject. More particularly, a method of providing a prognosis to a subject with cancer.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods and systems for measuring the intraocular pressure of an eye in a human. The methods include directing an acoustic incident wave at the surface of the eye to generate a reflected wave, measuring the coefficient of reflection of the incident and reflected waves, and determining the intraocular pressure of the eye from the coefficient of reflection. Also disclosed are methods of diagnosing glaucoma and/or intraocular hypertension.

IPC Classes  ?

• A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention provides an assay useful in predicting risk of capecitabine-induced toxicity in a subject. The subject may be screened for the presence of at least one polymorphism of the invention. Suitable polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing capecitabine-induced toxicity; a negative result may indicate a decreased risk of developing capecitabine-induced toxicity.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method for delaminating an electrode material of an electrode sheet from a current collector of the electrode sheet comprises positioning the electrode sheet in a sonicating bath, and at least partially within a target area of a sonotrode, wherein, in the target area, the distance between a front face of the sonotrode and the electrode sheet is less than or equal to 2 cm; and ultrasonically treating the electrode sheet, using the sonotrode, with a power density at the sonotrode front face greater than or equal to 50 W/cm2. An electrode material delaminating apparatus for performing the method is also disclosed.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• B09B 3/30 - Destroying solid waste or transforming solid waste into something useful or harmless involving mechanical treatment

Abstract

The invention relates to agents for use in preventing or reducing the interaction between S100 A8/A9 and GPIbα. Such agents are particularly for use in treating or preventing one or more inflammatory and/or thrombotic disease, such as cardiovascular diseases, chronic inflammatory diseases, infectious diseases and autoimmune diseases. An agent of the invention may be an antibody, a small molecule inhibitor, a peptide, a polypeptide, a recombinant protein, a nucleic acid, a T-cell receptor (TCR), an affibody, an aptamer, or a glycosaminoglycan.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/727 - HeparinHeparan

Abstract

A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to methods for determining whether a patient suspected of being infected with Mycobacterium tuberculosis has an active or latent tuberculosis infection; to the use of certain Mycobacterium tuberculosis proteins as biomarkers for diagnosing latent tuberculosis infections; to a kit of parts comprising the Mycobacterium tuberculosis proteins; and to methods of treating latent tuberculosis infections.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method of recycling lithium ion battery material which comprises the following steps: • comminution of lithium ion battery material to generate comminuted battery material and producing a single fraction comprising pieces of battery material; subjecting the single fraction to electrostatic separation to remove insulators and provide a conductive fraction; separating the conductive fraction using magnetic separation.

IPC Classes  ?

• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• B02C 1/00 - Crushing or disintegrating by reciprocating members
• B03C 1/00 - Magnetic separation
• B03C 7/00 - Separating solids from solids by electrostatic effect

Abstract

Disclosed are shear-thinning hydrogel compositions comprising 0.1 to 5 wt. % (such as 0.1 to 2.5 wt. %) of a microgel particle-forming polymer; and 0.5 to 100 mM of a monovalent and/or polyvalent metal ion salt as a cross-linking agent. The microgel particle-forming polymer is dispersed in an aqueous vehicle, and the hydrogel composition has a pH within the range of 3 to 8. The viscosity of the gel composition reduces when the gel is exposed to shear. Also disclosed are methods of making such compositions, and medical uses of such compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The disclosure relates to methods and apparatus for identifying rheological properties of liquids from acoustic signals generated by liquid flow through a pipe. Example embodiments include a method of identifying a rheological property of a liquid flowing in a pipe (101), the method comprising: detecting an acoustic signal generated by the liquid flowing in the pipe using a sensor (105) attached to a rod (104) extending from a wall of the pipe (101) into the liquid; sampling the acoustic signal to provide a sampled acoustic signal; transforming the sampled acoustic signal to generate a sampled frequency spectrum; correlating the sampled frequency spectrum with a stored frequency spectrum from a database of stored frequency spectra of liquids having predetermined rheological properties; and identifying a rheological property of the liquid based on the stored frequency spectrum.

IPC Classes  ?

• G01N 29/14 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object using acoustic emission techniques
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G01N 29/44 - Processing the detected response signal
• G01N 29/50 - Processing the detected response signal using auto-correlation techniques or cross-correlation techniques

Abstract

An apparatus for driving atoms of an atom cloud into a targeted quantum state is provided, the apparatus comprising: an atom source for releasing a cloud of atoms to be driven into a targeted quantum state; a laser system configured to generate a laser beam to be directed onto the atom cloud in use, the laser beam having a frequency corresponding to a resonant frequency of an atomic transition for exciting the atoms into the targeted quantum state; a modulator configured to, in use, modulate the frequency of the laser beam responsive to an input signal; a waveform generator coupled to the modulator and configured to, in use, generate an input signal for the modulator, wherein the input signal is arranged to cause the modulator to modulate the laser light to generate a comb of frequencies around the resonant frequency of the atomic transition, the frequency comb including a plurality of peaks, each peak being separated by a frequency spacing, δω, that is determined based on a Rabi frequency, Ω, of the atomic transition to drive atoms of the atom cloud into a targeted quantum state.

IPC Classes  ?

• G01V 7/04 - Electric, photoelectric, or magnetic indicating or recording means
• G01V 7/14 - Measuring gravitational fields or wavesGravimetric prospecting or detecting using free-fall time

Abstract

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and/or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 3/14 - Arrangements specially adapted for eye photography
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes

Abstract

A method for controlling a wind turbine system connected to a power grid. The method comprises generating a wind turbine control signal based on a power control reference for controlling a power output of a wind turbine; monitoring an electrical frequency of the power grid; in response to detecting a change in the frequency in the power grid, activating a fast frequency support method comprising the steps of; adjusting the power control reference to cause an overproduction of power by the wind turbine; the overproduction of power causing a transfer of inertial kinetic energy from the wind turbine to electrical power; wherein the power control reference is determined by applying an adaptive gain function to a measurement of a difference in grid frequency from a nominal level.

IPC Classes  ?

• F03D 7/02 - Controlling wind motors the wind motors having rotation axis substantially parallel to the air flow entering the rotor
• F03D 9/25 - Wind motors characterised by the driven apparatus the apparatus being an electrical generator
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks

Abstract

The present invention relates to a method for identifying whether or not it may be appropriate to administer to a subject a therapy for alleviating any potential consequences which may arise due to the subject having an atrial fibrillation (AF), the method comprising detecting, in a sample of fluid from the subject, a level of ccl21 and/or ddit4 expression and determining whether or not it may be appropriate to administer to the subject a therapy for alleviating any consequences which may arise due to the subject having AF, based upon the ccl21 and/or ddit4 expression level detected. Also provided are an anticoagulant or other AF therapy and a method of administering an anticoagulant drug or another AF therapy.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Abstract

The invention relates to a method of synthesising a modular polynucleotide, in one reaction, from two or more subunits that are each less than 100 base pairs in length.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/531 - Production of immunochemical test materials
• G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 49/00 - Preparations for testing in vivo
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided are compositions that include one or more synthetic target peptides, wherein each synthetic target peptide is about or at least 8-50 amino acids long; and has an amino acid sequence as set forth in Table 2 and/or Table 3. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro population of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically binds to a complex of an MHC class I molecule and a peptide having an amino acid sequence as set forth in Table 2 and/or Table 3, methods for treating and/or preventing cancers by administering a therapeutically effective dose of a composition that includes at least one target peptide having an amino acid sequence as set forth in Table 2 and/or Table 3.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

A method of isolating or suppressing forced oscillations in a power grid by utilising a wind turbine system comprising a wind turbine for capturing wind power, a generator driven by the wind turbine, and a power converter configured to control the rotational speed of the generator for controlling a supply of active power to the power grid. The power converter is further configured to supply reactive power to the power grid independently from the supply of active power. The method comprising the steps of: obtaining measurements of a forced oscillation occurring within the power grid; controlling the converter to supply active and reactive corrective oscillating power to the power grid in response to the measured forced oscillation such that the corrective oscillating power suppresses the forced oscillations.

IPC Classes  ?

• H02J 3/24 - Arrangements for preventing or reducing oscillations of power in networks
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
• H02J 3/50 - Controlling the sharing of the out-of-phase component

Abstract

A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.

IPC Classes  ?

• G02F 1/365 - Non-linear optics in an optical waveguide structure
• G02F 1/35 - Non-linear optics
• G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• G02F 1/37 - Non-linear optics for second-harmonic generation

Abstract

An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.

IPC Classes  ?

• G01V 7/00 - Measuring gravitational fields or wavesGravimetric prospecting or detecting

Abstract

The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 ? 54, which may be encoded by SEQ ID NOS: 55 ? 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 – 54, which may be encoded by SEQ ID NOS: 55 – 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present disclosure relates to methods and products for use in detecting target RNA sequences in a sample, based on a process which nicks the DNA strand of a DNA/RNA duplex and amplifies a product thereof

IPC Classes  ?

• C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction

Abstract

A system for improving cognitive function is disclosed. The system comprises a non- invasive brain stimulation device (150); a human computer interface; and a computer (101) configured to control the non-invasive brain stimulation device (150) and the human computer interface. The computer (101) controls the brain stimulation device (150) and the human computer interface to assess a subject's baseline cognitive function by interaction with the subject using the human computer interface. If the subject's baseline cognitive function is impaired, the computer (101) uses the human computer interface to provide the subject with a strategy for improving performance in a cognitive function test and stimulates the subject's brain with the non-invasive brain stimulation device (150) while training the subject's cognitive function.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present disclosure describes, in part, a polymer, for example a thermoplastic polyurethane elastomer, comprising one or more subunits comprising (i) at least one dianhydrohexitole moiety (ii) at least one urethane moiety and (ill) a thiol moiety having two or more sulphur atoms. The thermoplastic polyurethane elastomers may be biodegradable and possess excellent thermoplastic properties, including outstanding toughness, resulting from its semi-crystallinity and low glass transition temperature, that surpasses many leading plastics such as nylon 6 and high-density polyethylene (HOPE) and methods of making same.

IPC Classes  ?

• C08G 18/24 - Catalysts containing metal compounds of tin
• C07C 319/00 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides
• C08G 18/32 - Polyhydroxy compoundsPolyaminesHydroxy amines
• C08G 18/67 - Unsaturated compounds having active hydrogen
• C08G 18/80 - Masked polyisocyanates
• C08G 18/81 - Unsaturated isocyanates or isothiocyanates
• C08F 228/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
• C08G 75/14 - Polysulfides
• C08J 5/18 - Manufacture of films or sheets
• C08L 75/04 - Polyurethanes
• C08L 81/04 - Polysulfides

Abstract

The present invention relates to a system and a device for use in the diagnosis of an oral disease. Methods, kits and compositions for use in the diagnosis of oral disease are also provided. More particularly, the invention relates to a system comprising a probe which is configured to collect a fluid sample from the oral cavity of a subject, and a detector which is configured to detect in the fluid sample the presence and/or concentration of an analyte which is indicative of the oral disease.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• A61K 49/00 - Preparations for testing in vivo
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The disclosure relates to a desalination system and a method for operating the desalination system. Example embodiments include a desalination system (100) comprising a partitioned container (101), a membrane container (104) housing a cross- flow semipermeable membrane (105), a feed pump (108) for supplying saline water, a recirculation pump (109), a main valve (110), a bypass valve (111) and a purge valve (112). The system (100) operates in a first pressurisation stage where saline water is provided by the feed pump (108) while the bypass valve (111) is open, followed by a second pressurisation stage where an upstream compartment (114) of the container (101) is filled and a recharge stage where the main valve (110) is closed and concentrated saline water is purged via the purge valve (112). An inlet valve (116) may be provided, which is closed in the first pressurisation stage and open in the second pressurisation stage and recharge stage.

IPC Classes  ?

• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

The invention relates to a genetic probe, wherein the genetic probe comprises: an oligonucleotide, or an oligonucleotide analogue, with a Raman-active moiety incorporated therein, wherein the Raman-active moiety is incorporated into a base of the oligonucleotide or oligonucleotide thereof; and associated methods, uses, kits and compositions for determining a single point variant nucleotide in a target nucleic acid.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

The present invention relates to a drug delivery system and methods of using the delivery system, particularly a delivery system for transporting pharmaceutically active agents across, for example, the skin, the surface of the eye or mucosal membranes. The drug delivery system comprises a pharmaceutically effective moiety and a polyamine or amine moiety, wherein the polyamine or amine moiety does not comprise two or more contiguous basic amino acid residues. The drug delivery system may be provided for use as a medicament, or for use in the treatment of a disease or condition selected from eye disease, burns, infection, and trauma. The invention also provides a method comprising administering a pharmaceutically effective amount of the drug delivery system of the invention to a patient in need thereof.

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

P302170WO 32 ABSTRACT Magnetometer A sensor head for a Nonlinear Optically Pumped Magnetometer, NOPM, sensor system is 5 provided, wherein the sensor head is configured to receive a laser beam from a polarisation-maintaining optical fibre, the sensor head comprising: a polariser arranged to receive a laser beam output from the polarisation-maintaining optical fibre, the polariser for cleaning the polarisation of the received laser beam to remove orthogonally polarised light created by birefringence introduced into the polarisation-maintaining optical fibre; a non-10 polarising beam splitter arranged to receive the polarised laser beam from the polariser; a first photodetector arranged to receive a portion of the light reflected on a first pass through the non-polarising beam splitter, the first photodetector for detecting and stabilising a power of the laser beam received in the sensor head; a vapour cell for receiving polarised light of the laser beam transmitted on the first pass through the non-15 polarising beam splitter, the vapour cell containing an atomic medium that, when optically pumped with the polarised light of the laser beam nearly resonant with an atomic transition of the atoms, polarises the atoms inducing a dipole susceptible to rotation in the presence of an external magnetic field; a mirror adjacent the vapour cell and arranged to retroreflect the laser beam traversing the vapour cell back along its incident optical path to the non-20 polarising beam splitter; and a polarimeter arranged to receive the laser beam reflected on a second pass through the non-polarising beam splitter, the polarimeter for detecting a rotation of polarisation of the laser beam passing through the vapour cell due to the external magnetic field. 25

IPC Classes  ?

• G01R 33/26 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux using optical pumping